{"id":"W4328053701","doi":"10.1016/j.jtho.2023.03.016","title":"Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"Daiichi Sankyo Europe; National Cancer Institute; Genentech; Ignyta; Eli Lilly and Company; Associazione Italiana per la Ricerca sul Cancro; EMD Serono; Foundation Medicine; Galecto; BeiGene; Mirati Therapeutics; AstraZeneca; Novocure; Jazz Pharmaceuticals; Merck KGaA; Revolution Medicines; Regeneron Pharmaceuticals; Pfizer; Incyte; F. Hoffmann-La Roche; Sanofi; GlaxoSmithKline; Spectrum Pharmaceuticals; Amgen; Agenzia Italiana del Farmaco, Ministero della Salute; PharmaMar; Celgene; Bristol-Myers Squibb","keywords":"Medicine; Open label; Exon; Cohort; Oncology; Internal medicine; Cancer research; Clinical trial; Gene; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007164503,0.000266971,0.00097536,0.000679782,0.0001370038,0.00006461766,0.0002273093,0.0001808685,0.0001473541],"category_scores_gemma":[0.0003806358,0.0002070869,0.0001667346,0.0006481851,0.00008159877,0.0004019532,0.00007184137,0.0003609287,0.00007967649],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001664792,"about_ca_system_score_gemma":0.001262482,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002681826,"about_ca_topic_score_gemma":0.0002045423,"domain_scores_codex":[0.9975103,0.0002871289,0.001111787,0.0003291994,0.0003242188,0.0004373675],"domain_scores_gemma":[0.9980279,0.0004064523,0.0007088704,0.0002691125,0.0002898468,0.0002978705],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2079978,0.04106729,0.04335821,0.0001706984,0.005041718,0.01736563,0.00889174,0.0003065861,0.01037385,0.00006218303,0.004407038,0.6609572],"study_design_scores_gemma":[0.8010752,0.05596287,0.03430878,0.001362493,0.00824916,0.001540442,0.006197543,0.006356949,0.003105462,0.0002597906,0.08082802,0.0007533595],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9891481,0.0004915312,0.0001008072,0.003174956,0.00179722,0.002562219,0.00004916837,0.00004635167,0.002629662],"genre_scores_gemma":[0.9885278,0.0006687183,0.006169192,0.0002894841,0.0007700083,0.0003066385,0.0001198088,0.0000579027,0.003090405],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6602039,"threshold_uncertainty_score":0.844476,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08658018113189056,"score_gpt":0.5278038491763837,"score_spread":0.4412236680444931,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}